Akoya acquired the Phenoptics portfolio in 2018 to provide, in combination with CODEX, a spectrum of powerful tools spanning biomarker discovery to clinical research applications. The story of Phenoptics begins much earlier, however, at Cambridge Research & Instrumentation (CRI). CRI was co-founded by Peter Miller and Cliff Hoyt, and it was where they commercialized the revolutionary multispectral imaging technology. Peter is now VP of Research & Development at Akoya Biosciences, and Cliff is VP of Translational & Scientific Affairs.
We asked Peter to walk us through the path he and Cliff took to bring multispectral imaging to the life sciences. They took a winding road, working with lasers, NASA, and the telecom industry, before focusing their efforts on multiplexed tissue imaging and analysis.